Reaction

Paronychia reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 4,271 reports · 113 co-occurring drugs

As of the last recalculation, Paronychia appears in 4,271 FAERS reports alongside 113 co-occurring drug terms. The strongest observed disproportionality signal is PANITUMUMAB (PRR 208.6).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Panitumumab	580	208.6	216.7
Gefitinib	126	70.1	71.0
Erlotinib	113	58.4	59.0
Lapatinib	174	56.9	57.6
Erlotinib Hydrochloride	134	53.8	54.4
Cetuximab	262	43.3	43.7
Osimertinib	225	36.1	36.3
Ado-Trastuzumab Emtansine	52	30.4	30.6
Irinotecan Hydrochloride	71	27.3	27.5
Oxaliplatin	368	26.4	26.5
Fluorouracil Cream, 0.5%	357	24.8	24.9
Fluorouracil	357	24.4	24.6
Pemetrexed	96	22.3	22.4
Trametinib	103	21.3	21.3
Carboxymethylcellulose Sodium	39	20.4	20.5
Dronabinol	31	18.9	19.0
Pertuzumab	102	18.7	18.8
Capecitabine	305	17.4	17.5
Bleomycin Sulfate	36	17.1	17.2
Pemetrexed Disodium	116	15.2	15.3
Fosaprepitant Dimeglumine	39	13.9	14.0
Trastuzumab	182	13.5	13.5
Fam-Trastuzumab Deruxtecan-Nxki	27	13.1	13.2
Docetaxel Anhydrous	163	12.2	12.2
Docetaxel	163	12.2	12.2
Aprepitant	45	12.0	12.0
Granisetron Hydrochloride	22	10.3	10.3
Leucovorin Calcium	39	10.0	10.0
Dexamethasone Sodium Phosphate	20	9.6	9.7
Filgrastim	73	9.6	9.6
Fulvestrant	64	9.6	9.6
Encorafenib	19	9.4	9.4
Granisetron	19	8.9	8.9
Paclitaxel (Aibumin-Bound)	129	7.9	7.9
Regorafenib	18	7.6	7.6
Posaconazole Delayed-Release	17	7.6	7.6
Bevacizumab	184	7.5	7.5
Trazodone Hydrochloride	24	7.5	7.5
Paclitaxel	145	7.4	7.4
Mupirocin Calcium	20	7.1	7.1
Dabrafenib	29	6.7	6.8
Mupirocin	18	6.5	6.5
Carboplatin	162	6.4	6.4
Isotretinoin	63	6.3	6.3
Doxorubicin Hydrochloride	41	6.2	6.2
Doxycycline Hyclate	83	6.1	6.1
Doxycycline	83	6.0	6.0
Alemtuzumab	23	5.8	5.8
Lactulose	45	5.8	5.8
Cefepime Hydrochloride	19	5.8	5.8
Methylprednisolone Acetate	9	5.5	5.5
Amoxicillin And Clavulanate Potassium	29	5.2	5.2
Clobetasol Propionate Ointment Usp, 0.05%	11	5.2	5.2
Cephalexin	23	5.2	5.2
Clobetasol Propionate	11	5.2	5.2
Posaconazole	17	5.1	5.1
Magnesium Oxide	43	5.0	5.1
Itraconazole	12	5.0	5.0
Canakinumab	11	5.0	5.0
Loperamide Hcl	13	4.9	4.9
Zoledronic Acid	40	4.9	4.9
Azacitidine For	18	4.8	4.8
Loperamide Hydrochloride Oral	10	4.8	4.8
Amphotericin B	12	4.7	4.7
Crizotinib	12	4.6	4.6
Everolimus Tablets	15	4.4	4.4
Fludarabine Phosphate	35	4.4	4.4
Atropine	7	4.1	4.1
Cefepime	12	4.1	4.1
Letrozole	51	4.1	4.1
Mercaptopurine	14	3.9	3.9
Enoxaparin Sodium	46	3.9	3.9
Loperamide Hydrochloride	35	3.8	3.8
Pitavastatin Calcium	8	3.8	3.8
Gemcitabine Hydrochloride	41	3.8	3.8
Levofloxacin	45	3.7	3.7
Levofloxacin In 5% Dextrose	45	3.7	3.7
Ibrutinib	60	3.7	3.7
Doxorubicin	66	3.7	3.7
Exemestane	16	3.7	3.7
Pegaspargase	9	3.6	3.6
Thiotepa	7	3.6	3.6
Letrozole Tablets	35	3.6	3.6
Ondansetron	77	3.5	3.5
Ondansetron Tablets	77	3.5	3.5
Ondansetron Hydrochloride	86	3.5	3.5
Everolimus	36	3.5	3.5
Infliximab-Dyyb	20	3.3	3.3
Azacitidine	20	3.3	3.3
Vemurafenib	8	3.2	3.2
Ezetimibe And Simvastatin	10	3.2	3.2
Loperamide Hydrochloride And Dimethicone	21	3.2	3.2
Cisplatin	50	3.1	3.1
Timolol	7	2.8	2.8
Instalax Polyethylene Glycol 3350	7	2.8	2.8
Gemcitabine	22	2.7	2.7
Polyethylene Glycol 400	7	2.7	2.7
Selinexor	4	2.3	2.3
Brinzolamide	4	2.2	2.2
Hydromorphone Hydrochloride	42	2.2	2.2
Tofacitinib Citrate	6	2.2	2.2
Denosumab	91	2.2	2.2
Atezolizumab	16	2.0	2.0
Venetoclax	23	1.8	1.8
Obinutuzumab	6	1.8	1.8
Pegfilgrastim	35	1.7	1.7
Cabozantinib	17	1.7	1.7
Pembrolizumab	37	1.7	1.7
Axicabtagene Ciloleucel	3	1.5	1.5
Ravulizumab	4	1.4	1.4
Aflibercept	9	1.4	1.4
Olaparib	5	1.2	1.2
Bimekizumab	5	1.1	1.1

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.